A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
The disappointing Pynnacle trial is set to yield registrational data.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
A single but durable stable disease sends the microcap's stock up 730%.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A newly published cache of CRLs includes six novel oncology drugs.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
